I don't think you should be so quick to just assume a capital...

I don't think you should be so quick to just assume a capital raising is imminent. I think we should be ok until about march, by which time we should hopefully have interim results for 2 trials, and therefore if positive, allow for capital to be raised at a much higher SP, or maybe not even at all if a partnership is established.

Below is an excerpt from the September 2013 edition of Bioshares. I'll point out a part I was particularly interested in - that they expect the company to have sufficient cash to reach the milestone of interim results from all 3 trials over the next 6 months (i.e. up till march 2014).

"Greg Collier, the former CEO of Chemgenex Pharmaceuticals,
has returned to the Australian biotech sector with his next
drug development play, called Invion.
Invion has two drug candidates in three Phase II trials. The
first is being used to treat smoker's cough in smoking cessa-tion. The second is in asthma. And the third is in patients with lupus. And interim readout in all three trials is expected in over the next six months, and the company has sufficient cash to reach that milestone.
The company has a very experienced team, with James Campbell
(also previously at Chemgenex) as an executive director, and
Mitchell Glass as CMO, based in the US. Mitchell Glass has
put 50 drugs through clinic assessment and has been involved
with bringing five new drugs to market.

Bioshares recommendation: Speculative Buy Class A"

http://www.benitec.com/documents/1309_Bioshares_Update.pdf


I believe we have very good management and board members, who will ensure a raising takes place at a higher price than it is now, off the back of some positive news flow.

There is decent support around these levels, and anything below 8c is great buying imo